Compare ASTRAZENECA PHARMA with VENUS REMEDIES - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs VENUS REMEDIES - Comparison Results

Rs 100 invested in...

Loading...
DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ASTRAZENECA PHARMA VENUS REMEDIES ASTRAZENECA PHARMA/
VENUS REMEDIES
 
P/E (TTM) x 105.9 3.9 2,724.7% View Chart
P/BV x 14.2 0.8 1,865.9% View Chart
Dividend Yield % 0.1 0.0 -  

Financials

 ASTRAZENECA PHARMA   VENUS REMEDIES
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-21
VENUS REMEDIES
Mar-21
ASTRAZENECA PHARMA/
VENUS REMEDIES
5-Yr Chart
Click to enlarge
High Rs4,970314 1,582.3%   
Low Rs2,34822 10,577.5%   
Sales per share (Unadj.) Rs325.4444.2 73.3%  
Earnings per share (Unadj.) Rs37.350.1 74.6%  
Cash flow per share (Unadj.) Rs45.478.6 57.7%  
Dividends per share (Unadj.) Rs2.000-  
Avg Dividend yield %0.10-  
Book value per share (Unadj.) Rs181.8313.2 58.0%  
Shares outstanding (eoy) m25.0012.34 202.6%   
Bonus / Rights / Conversions 00-  
Price / Sales ratio x11.20.4 2,969.8%   
Avg P/E ratio x98.03.4 2,918.1%  
P/CF ratio (eoy) x80.62.1 3,771.0%  
Price / Book Value ratio x20.10.5 3,748.1%  
Dividend payout %5.40-   
Avg Mkt Cap Rs m91,4782,075 4,407.9%   
No. of employees `000NANA-   
Total wages/salary Rs m2,195460 477.1%   
Avg. sales/employee Rs Th00-  
Avg. wages/employee Rs Th00-  
Avg. net profit/employee Rs Th00-  
INCOME DATA
Net Sales Rs m8,1365,481 148.4%  
Other income Rs m128196 65.4%   
Total revenues Rs m8,2645,678 145.6%   
Gross profit Rs m1,355772 175.4%  
Depreciation Rs m201353 57.1%   
Interest Rs m11130 8.4%   
Profit before tax Rs m1,271486 261.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m338-132 -255.8%   
Profit after tax Rs m933618 151.1%  
Gross profit margin %16.714.1 118.2%  
Effective tax rate %26.6-27.2 -97.7%   
Net profit margin %11.511.3 101.8%  
BALANCE SHEET DATA
Current assets Rs m6,8872,316 297.4%   
Current liabilities Rs m3,734974 383.2%   
Net working cap to sales %38.824.5 158.3%  
Current ratio x1.82.4 77.6%  
Inventory Days Days4525 180.8%  
Debtors Days Days38213 17.9%  
Net fixed assets Rs m1,8553,243 57.2%   
Share capital Rs m50123 40.5%   
"Free" reserves Rs m4,4963,742 120.1%   
Net worth Rs m4,5463,865 117.6%   
Long term debt Rs m0468 0.0%   
Total assets Rs m8,7425,559 157.3%  
Interest coverage x117.64.7 2,486.5%   
Debt to equity ratio x00.1 0.0%  
Sales to assets ratio x0.91.0 94.4%   
Return on assets %10.813.5 80.3%  
Return on equity %20.516.0 128.4%  
Return on capital %28.214.2 198.5%  
Exports to sales %00-   
Imports to sales %29.30-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs m2,382NA-   
Fx inflow Rs m3180-   
Fx outflow Rs m2,3820-   
Net fx Rs m-2,0640-   
CASH FLOW
From Operations Rs m1,0481,326 79.0%  
From Investments Rs m1,730557 310.6%  
From Financial Activity Rs m-90-1,622 5.5%  
Net Cashflow Rs m2,688269 998.0%  

Share Holding

Indian Promoters % 0.0 40.8 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 3.6 0.3 1,081.8%  
FIIs % 2.4 0.3 721.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 25.0 59.2 42.2%  
Shareholders   57,760 19,952 289.5%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ASTRAZENECA PHARMA With:   CIPLA    SUN PHARMA    LUPIN    DR. REDDYS LAB    ZYDUS LIFESCIENCES    



Today's Market

Sensex Ends 236 Points Lower, Nifty Falls Below 16,150; IT & FMCG Stocks Witness Selling(Closing)

Indian share markets ended on a negative note today as global cues remained weak.

Related Views on News

Why Divi's Lab Share Price is Falling (Views On News)

May 24, 2022

Here's why Divi's Lab's stock fell over 10% in two days.

Divi's Lab Net Profit Rises 78%. Company Declares 1,500% Dividend (Views On News)

May 23, 2022

For full year, profit figures stood at Rs 29.6 bn as against Rs 19.8 bn for the previous year, reflecting a growth of 49%.

Dr Reddy's Net Profit Falls 76%. Company Declares 600% Dividend (Views On News)

May 19, 2022

During Q4, there were many changes to the products forming part of Dr Reddy's generics and proprietary products segments.

Cipla vs Sun Pharma: Which Pharma Stock is Better? (Views On News)

Apr 13, 2022

The pandemic has opened up new opportunities for the Indian pharmaceutical sector. Which company is set to benefit from it?

Nifty Pharma Index - Bulls are Losing the Ground (Views On News)

Mar 16, 2022

For the Nifty pharma index, it seems as if bulls are losing ground as they witness multiple bearish candlestick patterns.

More Views on News

Most Popular

2022's Best Performing Penny Stocks So Far...(Views On News)

Mar 2, 2022

We are just two months into 2022 and several penny stocks that we track have already surged 5x.

5 Debt Free Penny Stocks with Good Profitability to Watch Out for in 2022(Views On News)

Mar 16, 2022

Debt free penny stocks are vital when it's a question of portfolio diversification in a volatile market. They can potentially offer good profitability in the long run.

Penny Stocks to Buy and Hold Beyond 2022(Views On News)

Apr 6, 2022

A step-by-step method to pick the best penny stocks for the long term.

6 Penny Stocks that Could Be Hidden Bluechips. Take a Look...(Views On News)

Apr 13, 2022

These penny stocks can become future multibaggers. Watch out for them.

Adani Power vs Tata Power: Which Power Stock is Better?(Views On News)

Feb 28, 2022

Rising electricity consumption provides a lot of scope for growth. Which company has a better chance at capturing it?

More

Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


May 24, 2022 03:31 PM

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA 5-YR ANALYSIS

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS